# EDGAR Filing Document

**Accession Number:** 0001501756
**File Stem:** 0001193125-23-085717
**Filing Date:** 2023-3
**Character Count:** 21453
**Document Hash:** 8ba23841b1fb135daaf16ad0778220be
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001193125-23-085717.hdr.sgml**: 20230330

**ACCESSION NUMBER**: 0001193125-23-085717

**CONFORMED SUBMISSION TYPE**: S-8

**PUBLIC DOCUMENT COUNT**: 5

**FILED AS OF DATE**: 20230330

**DATE AS OF CHANGE**: 20230330

**EFFECTIVENESS DATE**: 20230330

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Adverum Biotechnologies, Inc.
- **CENTRAL INDEX KEY:** 0001501756
- **STANDARD INDUSTRIAL CLASSIFICATION:** BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
- **IRS NUMBER:** 205258327
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** S-8
- **SEC ACT:** 1933 Act
- **SEC FILE NUMBER:** 333-271001
- **FILM NUMBER:** 23781401

**BUSINESS ADDRESS:**
- **STREET 1:** 100 CARDINAL WAY
- **CITY:** REDWOOD CITY
- **STATE:** CA
- **ZIP:** 94063
- **BUSINESS PHONE:** (650) 649-1004

**MAIL ADDRESS:**
- **STREET 1:** 100 CARDINAL WAY
- **CITY:** REDWOOD CITY
- **STATE:** CA
- **ZIP:** 94063

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** Avalanche Biotechnologies, Inc.
- **DATE OF NAME CHANGE:** 20100921

**As filed with the Securities and Exchange Commission on March 30, 2023** 

**Registration No. 333-** 

------

**UNITED STATES SECURITIES AND EXCHANGE COMMISSION** 

**Washington, D.C. 20549** 

------

**FORM S-8** 

**REGISTRATION STATEMENT** 

***UNDER***

***THE SECURITIES ACT OF 1933***

------

## Adverum Biotechnologies, Inc.
**(Exact name of Registrant as specified in its charter)** 

------

---

| | |
|:---|:---|
| **Delaware** | **20-5258327** |
| **(State or other jurisdiction of**<br> **incorporation or organization)** | **(I.R.S. Employer**<br> **Identification Number)** |

---

---

| | |
|:---|:---|
| **100 Cardinal Way**<br> **Redwood City, California** | **94063** |
| **(Address of registrant's principal executive offices)** | **Zip code** |

---

------

**2014 Equity Incentive Award Plan, as amended and restated** 

**(Full title of the plans)** 

------

**Peter Soparkar** 

**Chief Operating Officer** 

**Adverum Biotechnologies, Inc.** 

**100 Cardinal Way** 

**Redwood City, California 94063** 

**(650) 656-9323** 

**(Name, address, including zip code, and telephone number, including area code, of agent for service)** 

------

***Copies to:***

**Kenneth Guernsey** 

**Cooley LLP** 

**3 Embarcadero Center, 20<sup>th</sup> Floor** 

**San Francisco, CA 94111-4004** 

**(415) 693-2000** 

------

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See definitions of "large accelerated filer," "accelerated filer," "smaller reporting company" and "emerging growth company" in Rule 12b-2 of the Exchange Act.

---

| | | | |
|:---|:---|:---|:---|
| Large accelerated filer | ☐ | Accelerated filer | ☐ |
| Non-accelerated filer | ☒ | Smaller reporting company | ☒ |
|  |  | Emerging growth company | ☐ |

---

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act. ☐

------

**Explanatory Note** 

This Registration Statement on Form S-8 (this "Registration Statement") registers an aggregate of 4,004,695 shares of the common stock, par value $0.0001 per share, of Adverum Biotechnologies, Inc. ("Common Stock") that may be issued and sold under the Adverum Biotechnologies, Inc. 2014 Equity Incentive Award Plan, as amended and restated ("2014 EIAP"), 1,065,030 of which are reserved for future issuance and 2,939,665 of which may be issued upon the exercise of outstanding options granted under the 2014 EIAP.

Pursuant to General Instruction E of Form S-8, this registration statement incorporates by reference the contents of the registration statements on Form S-8 relating to the 2014 EIAP filed by the Registrant with the Securities and Exchange Commission (the "SEC") on October 14, 2014 ([File No. 333-199296](http://www.sec.gov/Archives/edgar/data/1501756/000119312514371003/d803086ds8.htm)), April 14, 2015 ([File No. 333-203398](http://www.sec.gov/Archives/edgar/data/1501756/000119312515128949/d884936ds8.htm)), May 18, 2016 ([File No. 333-211439](http://www.sec.gov/Archives/edgar/data/1501756/000119312516594488/d193914ds8.htm)), June 2, 2017 ([File No. 333-218465](http://www.sec.gov/Archives/edgar/data/1501756/000119312517193055/d409270ds8.htm)), March 23, 2018 ([File No. 333-223894](http://www.sec.gov/Archives/edgar/data/1501756/000119312518094349/d545593ds8.htm)), and [March 7, 2019](http://www.sec.gov/Archives/edgar/data/1501756/000119312519067443/d720230ds8.htm) (as amended by [Post-Effective Amendment No. 1](http://www.sec.gov/Archives/edgar/data/1501756/000119312519071950/d706770ds8pos.htm) thereto filed on March 12, 2019 ([File No. 333-230138](http://www.sec.gov/Archives/edgar/data/1501756/000119312519071950/d706770ds8pos.htm))), March 12, 2020 ([File No. 333-237136](http://www.sec.gov/Archives/edgar/data/1501756/000119312520071731/d825175ds8.htm)), March 1, 2021 ([File No. 333-253727](http://www.sec.gov/Archives/edgar/data/1501756/000119312521063725/d61904ds8.htm)), and March 29, 2022 ([File No. 333-263954](http://www.sec.gov/Archives/edgar/data/1501756/000119312522088232/d354832ds8.htm)).

------

**PART I** 

**INFORMATION REQUIRED IN THE SECTION 10(A) PROSPECTUS** 

The information called for by Part I of Form S-8 is omitted from this Registration Statement in accordance with Rule 428 of the Securities Act, and the instructions to Form S-8. In accordance with the rules and regulations of the Commission and the instructions to Form S-8, such documents are not being filed with the Commission either as part of this Registration Statement or as prospectuses or prospectus supplements pursuant to Rule 424.

------

**PART II** 

**INFORMATION REQUIRED IN THE REGISTRATION STATEMENT** 

**Item 3. Incorporation of Documents by Reference.** 

The following documents have been filed by us with the SEC and are incorporated herein by reference:

• The contents of the earlier registration statements on Form S-8 relating
to the 2014 EIAP, previously filed with the SEC on October 14, 2014
([File No. 333-199296](http://www.sec.gov/Archives/edgar/data/1501756/000119312514371003/d803086ds8.htm)), April 
14, 2015 ([File No. 333-203398](http://www.sec.gov/Archives/edgar/data/1501756/000119312515128949/d884936ds8.htm)), May 
18, 2016 ([File No. 333-211439](http://www.sec.gov/Archives/edgar/data/1501756/000119312516594488/d193914ds8.htm)), June 
2, 2017 ([File No. 333-218465](http://www.sec.gov/Archives/edgar/data/1501756/000119312517193055/d409270ds8.htm)), March 
23, 2018 ([File No. 333-223894](http://www.sec.gov/Archives/edgar/data/1501756/000119312518094349/d545593ds8.htm)), and [March 7, 2019](http://www.sec.gov/Archives/edgar/data/1501756/000119312519067443/d720230ds8.htm) (as amended by [Post-Effective Amendment No. 1](http://www.sec.gov/Archives/edgar/data/1501756/000119312519071950/d706770ds8pos.htm) thereto filed on March 
12, 2019 ([File No. 333-230138](http://www.sec.gov/Archives/edgar/data/1501756/000119312519071950/d706770ds8pos.htm))), March 
12, 2020 ([File No. 333-237136](http://www.sec.gov/Archives/edgar/data/1501756/000119312520071731/d825175ds8.htm)), March 
1, 2021 ([File No. 333-253727](http://www.sec.gov/Archives/edgar/data/1501756/000119312521063725/d61904ds8.htm)), and March 
29, 2022 ([File No. 333-263954](http://www.sec.gov/Archives/edgar/data/1501756/000119312522088232/d354832ds8.htm));

• our [Annual Report on Form 10-K](http://www.sec.gov/Archives/edgar/data/../../../ix?doc=/Archives/edgar/data/0001501756/000162828023009899/advm-20221231.htm) for the year ended December 31, 2022, which was filed with the SEC on March 30, 2023 (our "Annual Report"), including the information to be incorporated by
reference in the Form 10-K by our proxy statement for our 2023 Annual Meeting of Stockholders; and

• the description of our common stock contained in our [Registration Statement on Form 8-A](http://www.sec.gov/Archives/edgar/data/1501756/000119312514282544/d765259d8a12b.htm) filed with the SEC on July 
28, 2014, including any amendments or reports filed for the purpose of updating such description, including [Exhibit 4.2](http://www.sec.gov/Archives/edgar/data/1501756/000162828021003623/advm-20201231xexx42.htm) to our Annual Report for
the year ended December 31, 2021, which was filed with the SEC on March 1, 2021.

All documents subsequently filed by the us pursuant to Sections 13(a), 13(c), 14 and 15(d) of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), other than current reports furnished under Item 2.02 or Item 7.01 of Form 8-K and exhibits furnished on such form that relate to such items, prior to the filing of a post-effective amendment to this Registration Statement which indicates that all of the shares of Common Stock offered have been sold or which deregisters all of such shares then remaining unsold, shall be deemed to be incorporated by reference in this Registration Statement and to be a part hereof from the date of the filing of such documents.

For purposes of this Registration Statement, any statement contained in a document incorporated or deemed to be incorporated by reference herein shall be deemed to be modified or superseded to the extent that a statement contained herein or in any other subsequently filed document which also is or is deemed to be incorporated by reference herein modifies or supersedes such statement. Any such statement so modified or superseded shall not be deemed, except as so modified or superseded, to constitute a part of this Registration Statement.

------

**Item 8. Exhibits.** 

**Exhibit Index** 

---

| | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|
|  |  |  | Incorporated by Reference | Incorporated by Reference | Incorporated by Reference | Incorporated by Reference |
| Exhibit<br>Number | Exhibit Description | Form | SEC File<br> No. | Exhibit Number | Date | Filed<br>Herewith |
| 4.1 | [Amended and Restated Certificate of Incorporation.](http://www.sec.gov/Archives/edgar/data/1501756/000156459017003759/advm-ex31_910.htm) | 10-K | 001-36579 | 3.1 | March 9, 2017 |  |
| 4.2 | [Amended and Restated Bylaws.](http://www.sec.gov/Archives/edgar/data/1501756/000119312520182655/d917807dex31.htm) | 8-K | 001-36579 | 3.1 | June 29, 2020 |  |
| 5.1 | [Opinion of Cooley LLP.](d479712dex51.htm) |  |  |  |  | X |
| 23.1 | [Consent of Independent Registered Public Accounting Firm.](d479712dex231.htm) |  |  |  |  | X |
| 23.2 | [Consent of Cooley LLP (included in Exhibit 5.1).](d479712dex51.htm) |  |  |  |  | X |
| 24.1 | [Power of Attorney (included on signature page hereto).](#sig) |  |  |  |  | X |
| 99.1 | [2014 Equity Incentive Award Plan, as amended and restated.](http://www.sec.gov/Archives/edgar/data/1501756/000156459019006536/advm-ex1012_914.htm) | 10-K | 001-36579 | 10.12 | March 6, 2019 |  |
| 107 | [Filing Fee Table.](d479712dexfilingfees.htm) |  |  |  |  | X |

---

------

**SIGNATURES** 

Pursuant to the requirements of the Securities Act of 1933, as amended, the Registrant certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on Form S-8 and has duly caused this Registration Statement to be signed on its behalf by the undersigned, thereunto duly authorized, in the City of Redwood City, State of California on March 30, 2023.

---

| | |
|:---|:---|
| **Adverum Biotechnologies, Inc.** | **Adverum Biotechnologies, Inc.** |
| By: | /s/ Laurent Fischer |
|  | Laurent Fischer, M.D. |
|  | President and Chief Executive Officer<br>(Principal Executive Officer) |

---

**POWER OF ATTORNEY** 

KNOW ALL PERSONS BY THESE PRESENTS, that each person whose signature appears below constitutes and appoints Laurent Fischer and Linda Rubinstein, and each one of them, his or her true and lawful attorney-in-fact and agent, with full power of substitution and resubstitution, for him or her and in his or her name, place and stead, in any and all capacities, to sign any and all amendments (including post-effective amendments) to this Registration Statement on Form S-8, and to file the same, with all exhibits thereto, and other documents in connection therewith, with the Securities and Exchange Commission (the "SEC"), and generally to do all such things in their names and behalf in their capacities as officers and directors to enable the registrant to comply with the provisions of the Securities Act of 1933, as amended, and all requirements of the SEC, granting unto said attorneys-in-fact and agents, and each of them, full power and authority to do and perform each and every act and thing requisite and necessary to be done in connection therewith, as fully to all intents and purposes as he or she might or could do in person, hereby ratifying and confirming all that said attorneys-in-fact and agents, or any of them, or their or his substitutes or substitute, may lawfully do or cause to be done by virtue hereof

Pursuant to the requirements of the Securities Act of 1933, as amended, this Registration Statement has been signed by the following persons in the capacities indicated.

---

| | | |
|:---|:---|:---|
| **SIGNATURE** | **TITLE** | **DATE** |
| /s/ Laurent Fischer | President and Chief Executive Officer and Director | March 30, 2023 |
| Laurent Fischer, M.D. | *(Principal Executive Officer)* |  |
| /s/ Linda Rubinstein | Chief Financial Officer | March 30, 2023 |
| Linda Rubinstein | *(Principal Financial Officer and Principal Accounting Officer)* |  |
| /s/ Patrick Machado | Chairman of the Board | March 30, 2023 |
| Patrick Machado |  |  |
| /s/ Soo Hong | Director | March 30, 2023 |
| Soo Hong |  |  |
| /s/ Mark Lupher | Director | March 30, 2023 |
| Mark Lupher, Ph.D. |  |  |
| /s/ Rabia Gurses Ozden | Director | March 30, 2023 |
| Rabia Gurses Ozden, M.D. |  |  |
| /s/ James Scopa | Director | March 30, 2023 |
| James Scopa |  |  |

---

------

---

| | | |
|:---|:---|:---|
| /s/ Dawn Svoronos | Director | March 30, 2023 |
| Dawn Svoronos |  |  |
| /s/ Reed Tuckson | Director | March 30, 2023 |
| Reed Tuckson, M.D. |  |  |
| /s/ Scott Whitcup | Director | March 30, 2023 |
| Scott Whitcup, M.D. |  |  |

---

## Exhibit 5.1

**Exhibit 5.1**![LOGO](g479712g0329114807487.jpg)

Sara Semnani

+1 310 883 6467

ssemnani@cooley.com

March 30, 2023

Adverum Biotechnologies, Inc.

100 Cardinal Way

Redwood City, CA 94063

**Re: Registration on Form S-8** 

Ladies and Gentlemen:

We have acted as counsel to Adverum Biotechnologies, Inc., a Delaware corporation (the "***Company***"), in connection with the filing of a registration statement on Form S-8 (the "***Registration Statement***") with the Securities and Exchange Commission (the "***Commission***") covering the offering of up to 4,004,695 shares (the "***Shares***") of the Company's Common Stock issuable pursuant to the Company's 2014 Equity Incentive Award Plan, as amended and restated (the "***Plan***").

In connection with this opinion, we have examined and relied upon the Registration Statement and related prospectus, the Company's certificate of incorporation and bylaws, each as currently in effect, the Plan and originals or copies certified to our satisfaction of such other records, documents, certificates, memoranda and other instruments as in our judgment are necessary or appropriate to enable us to render the opinion expressed below. We have assumed the genuineness of all signatures, the authenticity of all documents submitted to us as originals, the conformity to originals of all documents submitted to us as copies, the accuracy, completeness and authenticity of certificates of public officials, and the due authorization, execution and delivery of all documents by all persons other than the Company where authorization, execution and delivery are prerequisites to the effectiveness thereof. As to certain factual matters, we have relied upon a certificate of an officer of the Company and have not independently verified such matters.

Our opinion is expressed only with respect to the General Corporation Law of the State of Delaware. We express no opinion to the extent that any other laws are applicable to the subject matter hereof and express no opinion and provide no assurance as to compliance with any federal or state securities law, rule or regulation.

On the basis of the foregoing, and in reliance thereon, we are of the opinion that the Shares, when sold and issued in accordance with the Plan, the Registration Statement and related prospectus, will be validly issued, fully paid, and nonassessable (except as to Shares issued pursuant to deferred payment arrangements, which will be fully paid and nonassessable when such deferred payments are made in full).

Cooley LLP 1333 2nd Street Suite 400 Santa Monica, CA 94304

t: (310) 883-6400 f: (310) 883-6500 cooley.com

------

![LOGO](g479712g0329114807487.jpg)

March 30, 2023

Page Two

We consent to the filing of this opinion as an exhibit to the Registration Statement. In giving such consent, we do not thereby admit that we are in the category of persons whose consent is required under Section 7 of the Securities Act of 1933, as amended, or the rules and regulations of the Commission thereunder.

Sincerely,

**COOLEY LLP** 

---

| | |
|:---|:---|
| By: | /s/ Sara Semnani |
|  | Sara Semnani |

---

Cooley LLP 1333 2nd Street Suite 400 Santa Monica, CA 94304

t: (310) 883-6400 f: (310) 883-6500 cooley.com

## Exhibit 23.1

**Exhibit 23.1** 

**CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM** 

We consent to the incorporation by reference in the Registration Statement (Form S-8) pertaining to the 2014 Equity Incentive Award Plan, as amended and restated, of Adverum Biotechnologies, Inc. of our report dated March 30, 2023, with respect to the consolidated financial statements of Adverum Biotechnologies, Inc., included in its Annual Report (Form 10-K) for the year ended December 31, 2022, filed with the Securities and Exchange Commission.

/s/ Ernst & Young LLP

San Jose, California

March 30, 2023

## Ex-Filing

**Exhibit 107** 

**Calculation of Filing Fee Tables** 

<u>Form S-8</u> 

(Form Type)

<u>Adverum Biotechnologies, Inc.</u> 

(Exact name of Registrant as Specified in its Charter)

<u>Table 1 – Newly Registered Securities</u> 

---

| | | | | | |
|:---|:---|:---|:---|:---|:---|
| &nbsp;&nbsp;&nbsp;**Security Type** | **Security<br>Class Title** | **Proposed<br>Maximum <br>Offering<br>Price Per<br>Unit** | **Maximum<br>Aggregate<br>Offering Price** | **Fee Rate** | **Amount of<br>Registration<br>Fee** |
| &nbsp;&nbsp;&nbsp;Equity | Common Stock Other<sup>(2)</sup>1065030 <sup>(3)</sup> | $0.77<sup>(2)</sup> | $820073.10 | 0.0001102 | $91.00 |
| &nbsp;&nbsp;&nbsp;Equity | Common Stock Other<sup>(4)</sup>2939665 <sup>(5)</sup> | $0.75<sup>(4)</sup> | $2204748.75 | 0.0001102 | $243.00 |
| &nbsp;&nbsp;&nbsp;Total Offering Amounts | &nbsp;&nbsp;&nbsp;Total Offering Amounts |  | $3024821.85 |  | $334.00 |
| &nbsp;&nbsp;&nbsp;Total Fees Previously Paid | &nbsp;&nbsp;&nbsp;Total Fees Previously Paid |  |  |  |  |
| &nbsp;&nbsp;&nbsp;Total Fee Offsets | &nbsp;&nbsp;&nbsp;Total Fee Offsets |  |  |  |  |
| &nbsp;&nbsp;&nbsp;Net Fee Due | &nbsp;&nbsp;&nbsp;Net Fee Due |  |  |  | $334.00 |

---

(1) Pursuant to Rule 416(a) promulgated under the Securities Act of 1933, as amended (the "Securities
Act"), this Registration Statement shall also cover any additional shares of Registrant's Common Stock that become issuable under the plans set forth herein by reason of any stock dividend, stock split, recapitalization, or other similar
transaction effected without receipt of consideration that increases the number of outstanding shares of Registrant's Common Stock.

(2) Estimated in accordance with Rules 457(c) and (h) solely for the purpose of calculating the registration
fee on the basis of $0.77 per share, the average of the high and low prices of the Registrant's Common Stock on March 29, 2023 as reported on The Nasdaq Global Market.

(3) Represents shares of Common Stock that were automatically added to the shares reserved for issuance under the
Registrant's 2014 Equity Incentive Award Plan, as amended (the "2014 EIAP"), on January 1, 2023 pursuant to an "evergreen" provision contained in the 2014 EIAP and not subject to outstanding stock options. Pursuant to
such provision, the number of shares reserved for issuance under the 2014 EIAP automatically increased on January 1st of each year, starting on January 1, 2015 and continuing through January 1, 2024, by the lesser of (i) 4.0% of the total
number of shares of the Registrant's capital stock outstanding on December 31st of the immediately preceding calendar year, and (ii) a number determined by the Registrant's board of directors.

(4) Estimated pursuant to Rule 457(h) solely for the purpose of calculating the registration fee. The proposed
maximum offering price per share and proposed maximum aggregate offering price are calculated using a weighted-average exercise price for such shares.

(5) Represents shares of common stock that may be issued upon the exercise of outstanding options granted under the
2014 EIAP.